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To determine immune response to acute moderate-intensity aerobic exercise in breast 
cancer (BrCa) survivors compared with healthy controls. 15 sedentary females were age-matched 
to 21 BrCa survivors and performed 30 minutes of intermittent exercise at 60% wattage achieved 
at VO2peak. Hematological data was obtained, and immune cells were isolated from whole blood 
samples at rest and following exercise. All leukocyte populations significantly increased from 
pre to immediately post-exercise (P < 0.001) and returned to baseline values 1-hour post-exercise 
(P < 0.001). Exercise and recovery patterns from leukocytes, leukocyte subsets, and plasma 
volume shifts were similar between groups, except lymphocyte counts, which were significantly 
higher in controls (P < 0.001). BrCa survivors displayed similar immune responses to 30 minutes 
of moderate-intensity exercise to that of physically similar women without a history of cancer 
diagnosis. Although the results of this study are preliminary, they support findings from previous 
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At this time, breast cancer (BrCa) is the leading form of cancer diagnosed in women 
worldwide (66). Over the past two decades, advances in detection and anti-cancer treatments 
have led to improved survival rates and a shift in focus to post-treatment care of these patients. 
Many major BrCa treatments damage a myriad of physiological systems and are often 
accompanied by adverse side effects, including fatigue, reduced physical activity, 
immunosuppression, and ultimately reduced quality of life (19, 48, 60). Diminished immune 
function is a significant post-treatment concern that often increases susceptibility to secondary 
malignancies and other co-morbidities, such as cardiovascular disease, in BrCa survivors (33, 34, 
60). 
The immune system protects the body against harmful forces from within and outside the 
body. The innate immune system acts as the first line of defense by working against foreign 
pathogens. It is made up of cellular components (Natural Killer (NK) cells, granulocytes, and 
phagocytes), soluble factors (messenger proteins known as cytokines), and physical barriers 
(skin and mucous lining). Alternatively, the acquired immune system is a highly specialized 
system made up of cells that fight pathogens within the body (e.g. T and B cells). These cells 
produce immunological memory to each pathogen they come into contact in order to eliminate 
and prevent pathogen growth (20). A body of immuno-oncology studies have demonstrated that 
cancer treatment-induced impairments to both the innate and acquired immune systems disables 
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proper tumor antigen and other pathogen surveillance, consequently leaving this population more 
vulnerable to viral and bacterial infections (19, 32, 38, 40). The most common treatments, 
including chemotherapy, radiation, and surgical removal of tumors, have been shown to reduce 
total lymphocyte counts, T cell, B cell, and NK cell numbers, lessen cytolytic activity, impair 
antigen presentation, and decrease the vital functional capacity of these cells (4, 19, 31, 59, 61, 
71). Subsequently, there is a need to identify potential interventions that may improve immune 
system function following such cancer treatments.  
Mucosal associated invariant T (MAIT) cells are a unique subpopulation of pro-
inflammatory leukocytes that display both innate and acquired immune system characteristics 
(26). These innate-like T cells express the semi-invariant T cell receptor (TCR; iVa7.2-Ja33) and 
develop in the thymus. Once these cells are selected by the major histocompatibility complex 
(MHC) class I-related protein (MR1) on hematopoietic cells, they are directed through peripheral 
circulation to mucosal tissue of the liver, spleen, gastrointestinal tract, and the lungs (27, 69). 
MAIT cells are able to recruit other immune cells and respond to a diverse set of antigens via 
cytokine secretion (8, 15). As a relatively novel cell subset, MAIT cells continue to emerge as 
noteworthy players in the immune system. Alterations in circulating MAIT cells have been 
linked to an increasing number of clinical disorders including forms of cancer (15, 43, 56, 75). 
Compared to other T cell populations, MAIT cells may be able to persist through chemotherapy 
and even recover beyond baseline values in the months following chemotherapy, as 
demonstrated in BrCa survivors (15). If this is the case, this cell subpopulation may be 
potentially beneficial to immunosuppressed individuals such as BrCa survivors. Like other cell 
types though, MAIT cells must be mobilized and activated in order for their cell signaling and 
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killing capacity to be effective. As such, acute exercise may be an adjunct therapy of interest for 
this population. 
The interactions between exercise as a stressor and the immune system have been used to 
evaluate immunophysiological mechanisms for cellular mobilization. It is suggested that acute 
exercise induces similar physiological responses in the immune system to that of clinical 
stressors such as pathogen exposure, surgery, and trauma (54). Acute exercise can be used as a 
safe and effective way to stimulate the immune system. It is well established that acute exercise 
induces lymphocytosis and enhances cellular function (6, 25, 51). Many lymphocyte subtypes, 
including NK and T cells exhibit biphasic responses to acute exercise, where circulating cell 
numbers initially increase during exercise and then decrease back towards baseline levels during 
recovery (6). Since acute exercise has been shown to benefit immune surveillance and regulation 
via exercise induced stimulation of cells in healthy individuals, more studies are investigating the 
influence of exercise on immune responses in cancer populations. Previous research of this 
nature postulates that various forms of exercise may be associated with favorable immune 
outcomes. For instance, acute exercise has the ability to mobilize and activate cytotoxic immune 
cells that can assist in the directing of essential inflammatory signaling pathways (32, 52); a 
response that enables better pathogen defense and enhanced regulation of acute and chronic 
systemic inflammation (32, 40, 51, 53). To date, limited evidence exists evaluating immune 
response to specifically acute exercise in cancer populations (40). When compared to acute 
exercise studies using the same intensity and duration, cancer patients and survivors have similar 
immune cell response patterns but at lower magnitudes to that of healthy people (17, 40, 41, 63). 
MAIT cells on the other hand are an understudied cell type in exercise immunology. The only 
studies examining MAIT cell response to exercise were observed in healthy young men and 
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demonstrated that MAIT cells mobilize similarly to other T cell populations during an acute bout 
of exercise (28, 29). Furthermore, stimulated MAIT cells displayed increased TNF-α and IFN-γ 
cytokine expression, indicating a potential greater responsiveness to stimulation following 
acute exercise (28). All of these findings advocate for acute exercise as a potential up-regulator 
of a natural immune protective mechanism against disease susceptibility (19, 73). Many immune 
studies assess cell counts and proportions, however, to better understand the cellular response to 
acute exercise, function needs to be assessed. MAIT cell response to acute exercise has never 
before been studied in cancer survivors. As BrCa survivors tend to be at a higher risk for 
developing co-morbidities, such as clinical depression and anxiety, diabetes, cardiovascular 
disease, and secondary cancers (22),  following treatment care, examining MAIT cell function in 
BrCa survivors following acute exercise could potentially uncover clinically relevant 
connections to exercise and immune health in this diseased population. 
Purpose 
The purpose of this study was to investigate immune response to acute moderate intensity 
intermittent aerobic exercise in a BrCa survivor population compared with healthy but sedentary 
age-matched controls using hematological data.  
Research Questions 
1) Do leukocyte counts in the peripheral circulation change immediately or one-hour following 
a 30-minute bout of intermittent aerobic exercise at 60% peak wattage on a cycle ergometer? 
2) How do leukocyte counts in the peripheral circulation compare between BrCa survivors and 
age-matched controls with no history of cancer diagnosis following a 30-minute bout of 
intermittent aerobic exercise at 60% peak wattage on a cycle ergometer? 
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3) Does MAIT cell function in the peripheral circulation change immediately or one-hour 
following a 30-minute bout of intermittent aerobic exercise at 60% peak wattage on a cycle 
ergometer? 
4) How does MAIT cell function in the peripheral circulation compare between BrCa survivors 
and age-matched controls with no history of cancer diagnosis following a 30-minute bout of 
intermittent aerobic exercise at 60% peak wattage on a cycle ergometer? 
Research Hypotheses 
1) A 30-minute bout of intermittent aerobic exercise at 60% peak wattage on a cycle ergometer 
will increase leukocyte cell counts immediately post-exercise and return to baseline at one-
hour following exercise. 
2) Leukocyte counts in the peripheral blood circulation will be lower compared to healthy 
female controls, but counts will increase relatively similarly to the controls following a 30-
minute bout of intermittent aerobic exercise at 60% peak wattage on a cycle ergometer. 
3) A 30-minute bout of intermittent aerobic exercise at 60% peak wattage on a cycle ergometer 
will increase MAIT cell function immediately post-exercise and return to baseline at one-
hour following exercise. 
4) MAIT cell function will increase relatively similarly to the controls following a 30-minute 
bout of intermittent aerobic exercise at 60% peak wattage on a cycle ergometer. 
Delimitations 
• All participants were females.  
• All participants did not regularly participate in any exercise program 6 months prior to 
beginning the study, deeming them as sedentary.  
• All participants were familiarized with facilities, exercises, and testing protocols being used 
prior to taking baseline measurements in order to reduce any learning effect.  
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• All participants were recruited from the central North Carolina area via flyer, email, face to 
face, and phone call. 
• All participants were cleared by a physician for exercise participation prior to participating in 
the study.  
Assumptions 
• All participants followed the pre-assessment guidelines prior to testing sessions.  
• All participants gave their maximal effort during testing sessions.  
• Participants did not partake in any other forms of exercise or change of diet while 
participating in the study.  
• All participants honestly reported medical history and physical activity readiness. 
Limitations 
• The results of this study may only apply to those whom are women, apparently healthy but 
sedentary or have a BrCa history diagnosis, and at least 35 years of age or post-menopausal. 
Results may not be applied to females of all ages, males, or those with a history of other 
cancer diagnoses.  
• BrCa survivors included in this study all completed treatment within one year of participation 
but could be of any age. All healthy control participants were at least 35 years of age. 
• It is possible that participants did not adhere to pre-assessment guidelines entirely as 
researchers were not with them during the hours prior to testing.  










REVIEW OF LITERATURE 
This review is divided into six sections: Section I. Impact of Cancer Treatment on the 
Immune System, Section II. Exercise as Medicine for Cancer, Section III. Immune Response to 
Acute Exercise, Section IV. MAIT Cell Profile, Section V. PKC Pathway Activation via PMA-
Ionomycin, and Section VI. Justification of Methodology. 
Section I. Impact of Cancer Treatment on the Immune System 
At this time, BrCa is the leading form of cancer diagnosed in women worldwide. With 
30% of new cancer diagnoses in women being attributed to BrCa, cases total approximately 3.1 
million women in the United States with a history of BrCa diagnosis as of 2019 (66). Faster 
detection and anti-cancer treatment advances over the past three decades have led to increased 
longevity in oncology patients, especially in the BrCa population (60, 65). However, patients 
continue to face challenges into survivorship as many major cancer treatments diminish the 
function of physiological symptoms across the body and often result in a number of deleterious 
treatment-related side effects associated with reduced quality of life. Negative influences on 
physical characteristics such as reduced cardiac function and muscular strength, increased fat 
mass and reduced muscle mass, and chronic systemic inflammation and immunosuppression are 
among common treatment side effects that diminish overall quality of life and increase disease 
susceptibility in cancer patients (60). Thus, there is a need for interventions to effectively 
mitigate adverse symptoms, strengthen physiological systems involved in disease protection, and 
improve overall survivorship.  
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 As the primary protector against illness, the immune system plays a vital role in 
secondary cancer prevention and the development of other common comorbidities, such as 
cardiovascular disease, during survivorship. However, typical cancer treatments, including 
chemotherapy, radiation, and surgical removal of tumors have been linked to short- and long-
term weakened immunity. Specifically, decreased total lymphocyte counts, reduced T cells 
(CD4+, CD8+), B cells (CD19+), and NK cells (CD3-CD16+CD56+), and impaired T, B, and 
NK cell functional response has been shown in BrCa survivors who received chemotherapy (19, 
31, 59, 61). Radiation is another form of treatment that reduces total lymphocyte number, NK 
cell cytolytic activity, T cell ratios (CD4+/CD8+), and T and B cell proliferation responses to 
mitogenic stimulation (4, 19). Studies have also indicated that surgical interventions such as 
mastectomies, lumpectomies, and lymph node dissections can impair monocyte phagocytosis, 
antigen presentation, B cell immunoglobulin production, T cell response to mitogen stimulation, 
and decrease NK cell cytolytic activity (19, 71). Additionally, evidence suggests increases in 
proinflammatory cytokines and decreases in anti-inflammatory cytokines may be linked to 
concerning treatment related-side effects involved with systemic inflammation that has been 
correlated to changes in body composition and immunity (40). These deficits in baseline immune 
function may persist for weeks to years following the completion of treatment (9, 65). Although 
further research is needed linking changes in immune response directly to anticancer therapies, 
sufficient evidence suggests that such treatment related reductions in immune system function 
may put BrCa survivors at greater risk for cancer reoccurrence and additional comorbidities.  
Section II. Exercise as Medicine for Cancer 
During the past three decades, exercise as a Complementary Alternative Medicine 
(CAM), has received increased attention for its ability to mitigate some of these treatment-related 
side effects commonly experienced by cancer patients. Research conducted primarily in women 
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diagnosed with BrCa has shown that when administered prior, during, and post cancer treatment, 
exercise interventions decrease fatigue, improve strength and endurance, conserve muscle mass, 
improve metabolism, improve stress management, improve heart rate coherence and heart rate 
variability, and generally help patients feel better physically and emotionally (2). Exact 
mechanisms underlying the impact of exercise on the immune system in cancer patients still 
requires further study, nonetheless exercise has demonstrated its abilities to enhance immune 
surveillance and function through cellular mobilization, cytotoxic immune cell activation, and 
regulation of inflammatory signaling pathways (19, 32, 40). As a result of possible inflammation 
control, it is suggested that exercise may play a role in protecting against chronic inflammation-
associated diseases, including tumor growth (36, 40, 72). Exercise is a cost effective and natural 
strengthener to multiple physiological systems that aid in preventing secondary cancers and other 
co-morbidities (60). Whereas other adjuvant therapies tend to cause adverse side effects, are 
often expensive, and sometimes fail to control micro metastases (19).  
Although studies examining the effects of exercise in BrCa patients continue to rise, 
many fundamental questions remain with regard to optimal exercise prescriptions that include 
variation in exercise training type, intensity, duration, and frequency in addition to individualized 
care. To develop precise exercise guidelines specific for BrCa patients, the exercise oncology 
field is in critical need of studies with more detailed descriptions of testing and exercise 
prescriptions and studies that investigate specific physiological system responses in BrCa 
patients following exercise. 
Section III. Immune Response to Acute Exercise 
It is well established that single bouts of exercise, known as acute exercise, stimulate 
cellular immune responses in the body (6, 25, 51, 55, 62, 73). The human body responds to 
stresses placed upon it. For example, when the body is exposed to a pathogen, the immune 
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system forms a physiological response. The immune system also does this in response to 
physical stressors, such as exercise. In response to acute exercise stimuli, leukocyte populations, 
including NK cells, helper T lymphocytes (CD4+), cytotoxic T lymphocytes (CD8+), MAIT 
cells, and B lymphocytes (CD19+) tend to demonstrate a biphasic cell count response, where 
counts increase during exercise and decrease during recovery following exercise (6, 25, 29, 54) 
In regard to leukocyte subpopulation function in response to acute exercise, results vary. Some 
populations, such as neutrophil and lymphocyte apoptosis increase function during exercise and 
recovery, whereas others, such as lymphocyte proliferation in response to mitogens decrease 
function during exercise and recovery (54). Alternatively, NK cells increase function during 
exercise and decrease function during recovery (54). Duration and intensity of exercise impacts 
the magnitude of noted cellular immune responses, where lower intensities and shorter durations 
may not elicit as large of a response in comparison to greater intensities and longer durations (51, 
54, 73).  
When considering the relationship between exercise intensity and duration in cancer 
populations, the field of exercise immunology has developed the “J-shaped” hypothesis, which 
proposes an inverse relationship between exercise and illness susceptibility (19). Briefly, the 
hypothesis states that moderate intensity exercise may lead to enhanced immune function and 
consequently decreased disease risk, though exhaustive exercise and overtraining may lead to 
weakened immune function and therefore increased disease risk (19). However, no 
immunological mechanisms have been established linking exercise intensity and duration to 
cancer risk in humans, thus higher intensity exercise cannot infer clinical immunosuppression 
(54, 72). In fact, it has been discussed that markers of reduced immune cell number and function 
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during exercise recovery may be important for immune regulation and surveillance as opposed to 
being viewed as a state of immune vulnerability for the body (6). 
While a heap of immune-oncology evidence exists evaluating the effects of exercise 
training, few studies have examined the influence of specifically acute exercise on cellular 
immune responses in cancer populations. Six noteworthy studies have measured acute effects in 
pediatric, leukemia, prostate, and BrCa patients. Shore and Shepard (63) assessed changes in 
lymphocyte counts, cytolytic activity, and mitogen-induced lymphocyte proliferation in response 
to 30 minutes of exercise at ventilatory threshold in six children aged 10 to 14 years old, all who 
had been successfully treated for acute lymphoblastic leukemia. The six patients were all 
currently receiving chemotherapy or had completed chemotherapy treatment, and findings were 
compared to those of 11 healthy children. Similarly, Ladha et al. (41) investigated the effects of 
acute exercise on neutrophil count and function in four acute lymphoblastic leukemia patients 
between the ages of 7 to 18 years in comparison to six healthy matched controls. All participants 
completed a 30-minute exercise session consisting of intermittent run-walk intervals on a 
treadmill at 70%-85% of VO2peak (maximal oxygen consumption). Blood samples were collected 
for both studies at pre-exercise, post-exercise, and during recovery bouts 30-minutes to 2 hours 
post-exercise. Shore and Shepard (63) reported leukocytosis and lymphocytosis in both patients 
and controls. However, cell counts were lower in patients still receiving chemotherapy treatment, 
and T cell counts (CD3+, CD4+, CD8+) did not demonstrate changes from pre to post-exercise. 
The CD4+/CD8+ ratio was also lower pre-exercise when compared to post-exercise in the 
healthy group. Likewise, NK cell count (CD56+), cytolytic activity, and lymphocyte 
proliferation activity in patients receiving chemotherapy at the time of the study were lower 
compared to the healthy matched children. The authors observed significant increases in 
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neutrophil count from pre-exercise to immediately post-exercise (P = 0.011), significant 
decreases at 1-hour post-exercise (P = 0.045), and significant increases again from 1-hour to 2-
hours post-exercise. Similar changes in other measured immune components were observed, but 
no significant differences were observed between groups. 
Cancer treatment response was studied in six chronic myeloid leukemia patients in 
cytogenetic remission, as determined by BCR-ABL1 transcript levels following acute maximal 
exercise (37). Treatment response can be determined by measurements of BCR-AB1L transcripts 
in peripheral blood where a 2-5-fold increase indicates worrisome prognosis. As leukocyte 
composition may affect BCR-ABL1 quantification, Jönsson et al.(37) investigated changes in 
leukocyte composition in the peripheral blood before exercise, at maximal exhaustion, and 
during recovery of the maximal physical exercise test. A biphasic increase in leukocyte counts 
was observed and a shift in relative proportion of granulocytes changed significantly from pre to 
post-exercise (P < 0.001). BCR-ABL1 transcript levels increased 3.3-fold 180 minutes after 
exercise compared to baseline values (P < 0.01). Because BCR-ABL1 transcript levels increased 
in correlation to leukocyte content following acute exercise, it can be suggested that leukocyte 
composition in the peripheral blood should be considered when analyzing treatment response. 
Galvao et al. (23) examined the acute effects of heavy full body hydraulic and isotonic 
resistance training on immune response in ten prostate cancer patients undergoing androgen 
deprivation therapy. Blood samples were collected to analyze serum inflammatory markers (IL-
6, IL-8, IL-1ra, TNF-α, and CRP) and hematological variables pre and post-acute exercise at 
baseline prior to beginning a 20-week training program, at 10-weeks, and following the 20-
weeks of training. IL-8 tended to increase post-acute hydraulic exercise at 10 weeks into training, 
and IL-6 (P = 0.001) and TNF-α (P = 0.050) both significantly increased post-acute isotonic 
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exercise at week 20. At week 10, total leukocyte (P = 0.035) and neutrophil (P = 0.029) counts 
significantly increased following acute hydraulic exercise, whereas hemoglobin and all leukocyte 
counts (P < 0.05) increased following acute isotonic exercise at 20 weeks. 
The impact of acute exercise on NK cell response was studied in BrCa survivors by 
Evans et al. (17). Nine women with stage I to stage III BrCa who were 3-6 months post-
treatment were assessed in comparison to nine sedentary control women. All participants 
completed an acute bout of aerobic exercise on a cycle ergometer, which consisted of 10 three-
minute intervals at 60% of VO2peak. Blood samples were collected pre-exercise, immediately 
post-exercise, 2 hours post-exercise, and 24 hours post-exercise. NK cell counts significantly 
increased immediately following exercise in both groups (P = 0.004-0.008) and returned close to 
baseline values during recovery (P = 0.129-0.547). NK cell counts were significantly lower in 
the BrCa survivors when compared to the control women (P = 0.46). 
Finally, Zimmer et. al., investigated the short-term effects of a half marathon on T cells 
and pro-inflammatory cytokines in nine BrCa survivors compared to nine healthy age matched 
female controls (74). Blood samples were collected before, 15 minutes after, and 24 hours 
following the completion of a half marathon. Immune cell subsets showed similar mobilization 
behavior in the two groups revealing that NK cells and cytotoxic T cells demonstrated decreased 
proportions immediately following exercise with NK cells remaining below baseline levels and 
cytotoxic T cells recovering 24 hours post-exercise. However, helper T cell proportions (P = 
0.001) of the cancer survivors were significantly lower and cytotoxic T cell proportions (P < 
0.001) were significantly higher in comparison to the healthy controls. 
 Although many of these studies are preliminary in nature, this evidence suggests that 
acute exercise does stimulate immune cellular responses similar to that of healthy people with no 
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history of cancer diagnosis or treatment. Absolute cell counts may be lower in the cancer 
populations potentially due to immune damage induced by the cancer and/or cancer treatment 
therapies, but overall responses have shown to be comparable to controls. Collectively this 
supports that acute exercise does not disrupt normal immune responses in cancer people who 
indeed may have weakened immune systems. All of these studies discuss the importance of 
further research in this field in order to better understand immune responses in exercise oncology 
and work towards optimizing exercise prescription for this clinical population. 
Section IV. MAIT Cell Profile 
Mucosal associated invariant T cells are innate like T cells identified by a semi-invariant 
Va7.2-Ja33/12/20 T cell receptor on the cell membrane and high expression levels of CD161 (3, 
46). This undifferentiated subset of T cells undergoes three stages of development starting in the 
thymus. Here they are selected by the major histocompatibility complex (MHC) class I-related 
protein (MR1) on hematopoietic cells, which triggers the development of MAIT cell T cell 
antigen receptors (TCR), and they eventually egress to peripheral blood (26, 27). MAIT cells 
have minimal function before acquiring CD161 expression and exiting the thymus (46). 
However, once in the peripheral system, these cells are able to interact with B cells and 
commensal flora enabling further expansion and accumulation throughout mucosal tissues 
including the liver, lungs, gastrointestinal tract, and the spleen (15, 28, 46). MAIT cells’ primary 
role is antibacterial response following exposure to riboflavin metabolites (15, 27), though recent 
studies have demonstrated possible responses to viral infection as well (10, 21, 44). Riboflavin 
ligands bound to MR1 on antigen presenting cells can be identified by MAIT TCR. These then 
stimulate the early activation maker CD69 and the release of IL-2, IL-17, IFN-γ, and TNF-α (3, 
8, 15). As such, MAIT cells display the acquired characteristic of adapting to their environment 
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while also promoting innate immune responses, and in turn, enhance protection against infection 
(26). 
MAIT cells express a functional ABCB1 transporter that enables them to rapidly efflux 
drugs (14), with this characteristic potentially allowing MAIT cells to persist through 
chemotherapy unlike many other T cell populations that are damaged during this cancer 
treatment. To determine if this ABCB1 expression in MAIT cells could be correlated with 
cytotoxic drugs, Dusseaux et al. (14) collected blood samples from BrCa patients before, during, 
and after six cycles of anthracycline treatment. MAIT cell number decreased slightly after the 
third cycle of treatment and remained stable one-month after the sixth cycle. In comparison, 
CD4+ and CD8+ T cell number significantly decreased during chemotherapy and slightly 
recovered following treatment but remained significantly different than MAIT cell numbers. 
Perhaps this evidence suggests MAIT cells may be more resilient to chemotherapy than other 
immune cell populations and consequently beneficial to immune regulation for cancer survivors. 
It is important however to consider immune cell mobilization and function for effective 
immunity, which was not included in the analyses of the above study. 
 As previously discussed, acute exercise is known to mobilize the immune system (54, 58, 
73). As such, maximal and submaximal exercise has shown to increase MAIT cell frequency and 
number in healthy young males (28, 29). The primary mechanism behind lymphocytosis during 
exercise is due to the increase in circulating catecholamines, and more specifically, epinephrine. 
When epinephrine is released from the adrenal glands into circulation during exercise, 2-
adrenoreceptors on the cell surface allow for epinephrine to bind to these cells and downregulate 
adhesion molecules that bind the cells to the endothelial wall via secondary messenger systems, 
consequently releasing them into the peripheral blood (13). This process is known as adrenergic 
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leukocytosis, and the underlying mechanism is most likely due to the offset of these binding 
proteins. Additionally, increased shear stress may be a component in mobilizing lymphocytes. 
Increased blood pressure during exercise increases shear mechanical forces on the endothelial 
wall, which in turn may release cells into systemic circulation via alterations in binding proteins 
(64). MAIT cells are an understudied population in exercise immunology, but the few studies 
that have successfully researched this particular cell type have reasonable evidence to support 
acute exercise as a feasible and manipulatable stimulus for MAIT cell mobilization.  
While maximal exercise is not always feasible for some clinical populations, such as 
cancer survivors, submaximal exercise is an attractive alternative. Hanson and colleagues (28) 
demonstrated that MAIT cell numbers follow a partial biphasic response following submaximal 
exercise. Stimulated MAIT cells significantly increased TNF-α and demonstrated a trend for 
increases in IFN-γ expression, together indicating enhanced pathogen responsiveness following 
acute exercise (28). To date, MAIT cell response to acute exercise has never been studied in 
cancer. As such, this research could reveal important connections to acute exercise and immune 
health in this clinical population. 
Section V. PKC Pathway Activation via PMA-Ionomycin 
 Protein kinase C (PKC) pathways are physiologically fundamental for healthy cell 
regulation, proliferation, and survival (57). In the human body, PKC is a family of protein kinase 
enzymes that control the function of other proteins via phosphorylation, control the expression of 
genes relevant for cell cycle progression, and are activated through signal transduction (50). PKC 
pathways can be altered due to a multitude of reasons, including epigenetic changes that possibly 
result in cancerous cell growth. When cell signaling pathways have mutations, cellular processes 
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may be altered, so cancer cells that have been affected by treatments, such as chemotherapy or 
radiation, may not demonstrate normal activation responses (57). 
 
Figure 1. Schematic representation of calcineurin/NFAT signaling (67). 
Cytokines that are secreted by immune cells, such as activated T cells, work to regulate 
duration and intensity of immune responses. It is well established that insufficient or excessive 
cytokine production may correlate to the pathophysiology of many clinical conditions (1). 
Accordingly, T cell activation plays a vital role in immune regulation and disease prevention. In-
vivo, this response is elicited by viral or antigen presentation. Ex-vivo, this can be accomplished 
using chemicals such as phorbol 12-myristate 13-acetate (PMA) with ionomycin to stimulate 
activation markers in peripheral bound mononuclear cells isolated from whole blood (1). PMA is 
a small organic compound that diffuses across the cellular membrane into the cytoplasm of the 
cell, where it directly activates PKC (47). Ionomycin is a calcium ionophore that functions 
 
 18 
synergistically with PMA to trigger intracellular calcium release. Collectively, these two 
chemicals bypass the biological signaling cascade and directly activate the PKC pathway needed 
for nuclear factor of activated T cell (NFAT) signaling and cytokine production, a cascade that is 
typically initiated by ligand-surface receptor binding (1, 7, 11). 
 
 
Figure 2. Schematic representation of PKC activation via PMA (70). 
Section VI. Justification of Methodology 
 A brief explanation of certain methodology is provided as they were designed based off 
previous studies conducted by our authors.  
 Systemic epinephrine is known to stimulate androgenic leukocytosis around 70% of 
maximal oxygen uptake in healthy individuals (39). Evans et al. (17) conducted a study 
evaluating NK cell response to acute intermittent exercise in BrCa survivors compared to healthy 
controls. All participants performed a moderate bout of intermittent aerobic exercise on a cycle 
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ergometer at 60% of VO2peak, which resulted in significant increases in NK cell counts 
immediately following exercise (17). It is important to note that ventilatory threshold is known to 
lie at exercise intensities between 50-75% VO2max (5).  Hanson et al. (28) observed significant 
increases in MAIT cell counts and cytokine expression following submaximal acute exercise in 
healthy young men who cycled at 90% of ventilatory threshold, an intensity equivalent to 45-
68% of VO2max. Additionally, Hanson and colleagues (30) assessed stress hormone response to 
acute exercise in prostate cancer patients in comparison to controls. The participants 
intermittently exercised at 60% of the peak power output achieved during their VO2peak test. On 
average, control participants cycled at 77.6% (+/-6.4), prostate patients without androgen therapy 
cycled at 80.5% (+/-9.0), and prostate cancer patients on androgen therapy cycled at 84.8% (+/-
8.1) of their VO2peak (30). The studies described above were successfully conducted with similar 
clinical populations to that of the current study’s interest. This study utilized an acute, 
intermittent exercise bout on a cycle ergometer for immune stimulation. All participants cycled 
at 60% of VO2peak wattage; an intensity roughly equivalent to 70% VO2max, and about 10% 
greater than the intensity employed by Evans et al. (17). 
 Because MAIT cells elicit antibacterial responses, bacterial based stimulation assays are 
often used to examine MAIT cell function ex vivo. However, Hanson et al.(28) used PMA and 
ionomycin, a chemical based stimulant, to examine intracellular cytokine production, which was 
reproduced for the purposes of this study. Other stimulation models consisting of PFA, PHA, and 





Table 1. T Cell proliferation assays 
Author Title Population 
Exercise 
Involved 
Assay Summary Results 
Lancaster 
(2004) 




training on type 
and type 2 T 
lymphocytes. 









exercise, and 1-hour 
post-exercise. 10mg/µL 
BFA, 25ng/mL PMA, 1 
µg/mL ionomycin. 
- 4-hour incubation. 
Circulating CD3+ 






returned to baseline 















No PHA: resting blood was 
collected during several 
different timepoints 
during chemotherapy. 
CFSE labeled. 5 µg/mL 
PHA. 
-10-day culture. 
Defined MAIT cells 
as CD161, Va7.2+, 
CD4-, CD3+. 
Indicated MAIT 
cells are circulating 
lymphocytes with 
tissue tropism --> 











patients and 16 
age and sex 
matched healthy 
controls. 
No PMA/ionomycin assay: 
PBMCs stimulated with 
50 ng/mL PMA and 500 
ng/mL ionomycin for 4 
hours at 37 degrees C in 
5% CO2. 2uM of 
Monensin was added in 
the last 2 hours of 
culture. 
-4-hour culture. 
MAIT cells are 
reduced in the 
peripheral blood of 
multiple sclerosis 
patients and even 
more so in MS 







MAIT Cells are 
licensed through 
granzyme 






No 2% PFA-fixed E. coli: 
(20 min stimulation), 
then stained with CFSE 
and Cell Trace Violet 
(CTV). Mixed with 
enriched CD8+ T cells at 
various ratios for killing 
assay prep.  
MAIT cells are 
highly proliferative 






Granzyme B and A 
and perforin so 
MAIT cells can 
specifically kill 













No E. coli & 
PMA/ionomycin: 
Resting blood. 
Monocytes settled in 96 
well plate for 2 hours. E. 
coli was fed to 
monocytes for 3 hours. 
MAIT cells were 
identified as 
Va7.2+. Most 
optimal MAIT cell 
proliferation in 
response to E. coli 





Isolated Va7.2+ was 
added and stimulation 
time was dependent on 
concentration of anti-
CD28. Monensin and 
BFA added along with 
PMA cocktail to for 6 
hours. Va7.2+ cells were 
stained with CTV and 
left to culture for several 
days. 





















No PMA assay: PBMCs co-
cultured for 20 hours in 
human RF10 complete 
media in the presence of 
PFA-fixed DH5a. MAIT 
cell killing assay: rested 
overnight in RF10 
complete media. Washed 
then stained for 20 min 
with mAbs directed 
against CD2, CD161, 
TRAV1-2 as well as 
7AAD After culture, 
cells. Killing 20 hours. 
PMA 4 hours. E. coli 24 
hours. 
Frequency and 
function of MAIT in 
mm pt. b/c role in 
tumor immunity 
unknown. 
Frequency in blood 
decreased from 
healthy adults (but 
similar to elderly). 
Frequency decreases 
as a function of age. 
No significant 
difference in 




difference in mm 












patient, PBS pt., 
and PSC patient 
with and 
without IBD 
No E. coli assay: PBMC's 
stimulated for 24 h with 
E. coli or combo with 
IL-12 or IL-18 
-24-hour culture 
Impaired MAIT cell 
response to E. Coli 
stimulation with 
reduced levels of 
CD107a, TNF-α, 





















thawed, washed, and 
rested overnight. 
Stimulated for 4 hours 
with 2 ng/mL PMA and 
1µg/mL ionomycin at 37 
degrees Celsius and 5% 
CO2. Cells washed, 
fixed, and intracellularly 
stained (IFN-γ, TNF-, 
IL-17A) for 30 minutes 








returning to baseline 
(65%) at 1-hour 
post-exercise. IFN-γ 
increased with 





BrCa is the leading form of cancer in women worldwide(66). Due to physiologically 
destructive cancer treatments and common adverse treatment side-effects associated with 
increased disease susceptibility and decreased quality of life, there is significant need for 
complementary alternative therapies in the oncology community. Exercise has demonstrated 
promising positive influences on a myriad of physiological systems, including the immune 
system, which aids in illness protection for cancer survivors(2, 60). Acute exercise induces 
lymphocytosis in healthy individuals and cancer populations, with the magnitude of response 
correlating to intensity and duration of the exercise bout(17, 23, 37, 40, 41, 51, 54, 63). MAIT 
cells are identified by the semi-invariant T cell receptor (TCR) Va7.2-Ja33/12/20 displaying 
forms of innate and acquired immunity (26). These mucosal cells fight bacterial and potentially 
viral infections and have the transient ability to persist through chemotherapy making them a cell 
type of interest in clinical populations. MAIT cell counts and cytotoxic expression increase 
similarly to other lymphocytes in response to acute exercise in healthy men (28). However, 
MAIT cell immune response to acute exercise has never been studied in BrCa survivors or any 
cancer populations. Understanding MAIT cell response to acute exercise in cancer populations 















 15 middle aged females with no history of cancer diagnosis were recruited to complete 
this study. Participants were sedentary but otherwise healthy, as defined as participating in two 
or less days of physical activity per week within six months prior to participation. All 
participants were age-matched to the University of North Carolina at Chapel Hill’s ongoing Get 
REAL and HEEL BrCa survivor clinical trial participants. All BrCa survivor participants (n=21) 
were females who had histologically confirmed early stage (non-metastatic) BrCa, completed 
primary cancer treatment (chemotherapy, radiation, and/or surgery but may continue to be on 
endocrine therapy) within one year of taking part in the study, and were oncologist-approved to 
participate in exercise, but had no previous participation in UNC’s Get REAL and HEEL 
exercise program. Exclusion criteria for the healthy controls included: a medical history of BrCa 
diagnosis or cancer treatment (chemotherapy, radiation, surgery, or hormonal therapy), 
exercising more than two times per week for at least six months prior to beginning the study, any 
contraindications to participating in exercise, and pregnant women. The study was approved by 
the University of North Carolina at Chapel Hill’s institutional review board. Subjects signed an 
informed consent form prior to participation in the study. 
Study Design 
 During the initial visit, participants completed a medical history questionnaire, physical 
activity readiness questionnaire (PAR-Q), and informed consent was obtained. An International 
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Physical Activity Questionnaire (IPAQ) was completed to determine baseline physical activity 
levels for the purposes of matching. Baseline assessments took place over three days of testing. 
 On day one of testing, pre-assessment guidelines were reviewed with the participants, 
including confirmation of overnight fast, no alcohol consumption during the previous 24 hours, 
and no caffeine prior to testing, then anthropometric data, including height, weight, blood 
pressure, and resting heart rate were collected. Body composition was measured via dual energy 
X-ray absorptiometry (DXA) (Hologic Inc., Bedford, MA, USA; Apex Software Version 3.3), a 
12-lead resting electrocardiogram (EKG) (GE CASE Cardiosoft V. 6.6 ECG diagnostic system; 
General Electric, Palatine, IL, USA) was obtained, and familiarization for the cardiopulmonary 
exercise test (CPET) protocol was completed. 
 Participants reported back to the oncology lab approximately 3-7 days after the initial 
visit for day two of testing. Participants completed a cardiopulmonary graded exercise test on a 
cycle ergometer to determine maximal cycling power output (wattage) and VO2peak.  
 During visit three, blood samples were collected from participants at three separate time 
points via intravenous arm cannulation to evaluate blood biomarker responses to an acute 
exercise bout. First, resting blood samples were collected. Then participants completed a 
moderate intensity interval exercise trial. The acute exercise bout consisted of 10 3-minute 
intervals cycling on the cycle ergometer at 60% of maximal wattage achieved during VO2peak 
testing with 1.5 minutes of stationary rest between each interval. Additional blood draws were 
performed immediately post exercise and one-hour post exercise trial. 
 Peripheral blood mononuclear cells (PBMC) were isolated using density gradient 
centrifugation. PBMCs were counted and cryopreserved for storage at -80°C. Plasma and serum 
were isolated from the remaining whole blood and also frozen at -80°C for future analysis. Upon 
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time for analysis, PBMCs were thawed, treated and labeled with immunofluorescent antibody 
cocktail to distinguish specific cell type, and analyzed via flow cytometry (UNC Flow Cytometry 
CORE Lab) to determine Mucosal Associated Invariant T (MAIT) cell count and activation 
levels.  
Body Composition Assessment 
 Participants reported to the exercise oncology research lab and researchers confirmed that 
pre-assessment guidelines were followed. Participant height (Perspectives Enterprises, Portage, 
MI, USA) and body mass (Tanita Corp, Tokyo, Japan) were measured and recorded. Control 
participants who indicated they were not post-menopausal on the medical history questionnaire 
provided a urine sample for a pregnancy test. Upon a negative pregnancy test result, participants 
moved forward with testing and completed the body composition assessment. Participants were 
centered on the DXA table in the supine position. All metal or jewelry was removed prior to the 
scan. A full body DXA scan was completed for each participant using standard DXA screening 
procedures to record total body mass, compositional aspects of lean body mass (LBM), fat tissue 
mass (FM), and percentage body fat (% BF). Body mass was determined using a high-grade 
analytical balance-scale (accuracy  10 grams). 
Familiarization Session 
 Participants completed a cycling session on an electronically braked cycle ergometer 
(Lode, Groningen, Netherlands) for familiarization of the maximal cardiopulmonary exercise test 
(CPET) protocol, to be completed on day two. Seat height was adjusted to each individual to 
ensure proper cycling mechanics. Participants were fitted with a heart rate monitor (Polar FT1, 
Polar, USA, Port Washington, NY, USA) and respiratory mask headgear. Participants began the 
familiarization exercise test with a 2-minute warmup period on the cycle ergometer at zero 
resistance. Following the warmup, resistance increased to 20 watts for 3-minutes then increased 
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continually at 15 watts per minute. Participants cycled until they reached 75% of heart rate 
reserve which allowed them to experience the general protocol and associated equipment without 
reaching maximal exhaustion. 
Graded Exercise Test 
 Participant returned to the laboratory and researchers confirmed that pre-assessment 
guidelines were followed. All participants completed the CPET in the same manner as the 
familiarization session but continued to maximal exertion. Oxygen uptake and pulmonary 
ventilation was continuously recorded by a Parvo Medics’ TrueOne 2400 metabolic cart (Parvo 
Medics, Sandy, UT, USA), and breath by breath metabolic analysis was used to monitor whole 
body oxygen consumption (VO2). HR and RPE (6-20) were continuously monitored and 
recorded throughout the testing. Termination of the test was determined by either subject 
reaching volitional exhaustion and signaling to stop the test, VO2 plateau or decrease with 
increase in exercise intensity, or an abnormal subject response to the test was observed and 
therefore the research team terminated the test. 
Blood Draws 
 Participants reported back to the laboratory 1-7 days after completion of CPET, and 
researchers confirmed that the participants followed pre-assessment guidelines. Participants had 
a peripheral venous catheter inserted into the arm and secured with Tegederm dressing (BD 
Bioscience, Franklin Lanes, NJ, USA). Participants laid quietly for 10 minutes before the 
baseline blood sample was collected. The cannula was flushed with saline (0.9% NaCl) to avoid 
clotting. Flushing was repeated after all subsequent blood samples. Additional blood was drawn 
through the catheter at 0 hours after and 1 hour after the acute moderate intensity exercise bout 
following the same procedure as the baseline blood draw. 
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 Immediately post-exercise, the participants remained seated on the cycle ergometer and 
the second time point of blood was collected. Participants then cooled down while cycling at a 
light load (~10 watts) until heart rate and blood pressure approached baseline before moving to a 
chair for a 1-hour stationary recovery. During the recovery period, participants were given ad 
libitum access to water, but no other food or drink was consumed during this time before the 
final blood draw. At 1-hour post-exercise, a third blood draw was collected, and the cannula was 
removed. 
 Approximately 36 mL of blood were drawn into blood collection tubes containing EDTA 
and serum separators (BD Bioscience, Franklin Lanes, NJ, USA). The blood collection tubes 
were inverted several times and placed on ice for the duration of the visit until blood analysis.  
Exercise Trial 
 Participants completed an acute, intermittent standardized exercise protocol made up by 10 
intervals. Each interval consisted of 3 minutes of cycling at 60% of the peak wattage obtained 
during the CPET on day two of testing and was followed by 1.5 minutes of passive recovery 
without pedalling. A total of 30 minutes of exercise in a 45-minute session was used to stimulate 
the immune system, as used previously (30). Participants were fitted with a heart rate monitor and 
began the exercise trial with a 1-minute warm up period on the cycle ergometer at zero resistance. 
Following the warmup, resistance increased to half of the calculated 60% peak wattage for 1-
minute, then increased to the full 60% peak wattage for each 3-minute stage. HR and RPE (6-20) 
were recorded in the last 30 seconds of all stages. 
 Immediately post-exercise, the second blood draw was collected. During the next 1 hour 
of recovery, participants remained seated and were given ad libitum access to water, but no other 




 Immediately following each blood collection, complete blood counts (CBC) were run in 
duplicate with a maximal white blood cell difference of 0.1 cells/µL for each time point using a 
hematology analyzer (XP-300, Sysmex Corporation, Lincolnshire, IL, USA).  
Calculation of Plasma Volume Shifts 
 Exercise induced plasma volume shifts were calculated according to the equation given 
by Dill and Costill (12). The hematocrit and hemoglobin values that were used in these 
calculations were obtained from the complete blood count data pre-exercise, immediately post-
exercise, and 1-hour post-exercise. Plasma volume shifts were reported to estimate the effect that 
exercise had on fluid shifts, which may affect concentrations of leukocytes. 
Peripheral Blood Mononuclear Cells (PBMC) Isolation and Immunofluorescence Labeling 
Whole blood was diluted in a 1:1 ratio with phosphate buffered saline, and peripheral 
blood mononuclear cells (PBMCs) were isolated using SepMate tubes following manufacturer 
instructions (Stemcell, Vancouver, BC Canada). Cells were washed, counted via hemocytometer, 
and aliquoted for cryopreservation in 90% fetal bovine serum (FBA; VWR, Atlanta, GA, USA) 
and 10% DMSO (VWR, Atlanta, GA, USA), then stored at -80°C for future analysis. PBMCs 
were then thawed and used for immune cell phenotyping to conduct MAIT cell profile analysis.  
 MAIT cell phenotyping was determined using direct immunofluorescence labeling of cell 
surfaces with mouse anti-human monoclonal antibodies [CD3 (APC-Cy7); CD4 (BV510); CD8 
(AF700); CD69 (AF488); CD161 (BV605); TCR Vα7.2 (PE), Biolegend, San Diego, CA, USA)] 
in 100 µL of cell staining buffer (Biolegend, San Diego, CA, USA) for 15 minutes at 4°C in the 
dark, as performed and described previously (28). Excess antibody was washed, and cells were 




Cryopreserved PBMCs were available for all participants. PBMCs were thawed, washed 
with complete media (90% RPMI, 10% FBS, 1.0% penicillin-streptomycin; (Sigma Aldrich, St. 
Louis, MO, USA), and rested overnight at 37°C and 5% CO2. PBMCs were then stimulated for 
4 hours with 2 ng/mL of phorbol 12-myristate 13-acetate (PMA) and 1 µg/mL ionomycin (Sigma 
Aldrich, St. Louis, MO, USA) at 37°C and 5% CO2. Following the stimulation, cells were 
washed, and surface markers were labeled as described above. Cells were washed in 1x 
phosphate buffered saline and treated with a fixation and permeabilization kit (BD Biosciences 
Cytofix/Cytoperm, San Jose, CA, USA) following manufacturer instructions. To quantify 
cytokine production, intracellular staining was performed using mouse anti-human monoclonal 
antibodies in 100 µL of permeabilization buffer [IFN-γ (APC); TNF-α (BV650), Biolegend, San 
Diego, CA, USA)] for 30 minutes at 4°C in the dark. Cells were washed to remove excess 
antibody prior to being suspended in 200 µL of cell staining buffer for flow cytometry analysis. 
Flow Cytometry 
All cells were analyzed using flow cytometry (BD Biosciences, CA USA) and FlowJo 
CE software. Titrations were performed on all antibodies to determine optimal staining 
concentration, and appropriate fluorescence minus one (FMO) controls were included in 
analyses. Single cells were determined using forward light-scattering properties for width and 
height. Lymphocytes were identified and gated using the forward and side light-scattering 
properties. To determine MAIT cell populations, VA7.2+CD161+ was identified as MAIT cells 
from the CD3+ population with gating on CD8+ and CD4+ to identify specific subpopulations. 
To determine proportion of MAIT cells within the traditional cytotoxic T lymphocyte (CD8+) 
populations, CD3+ was used to identify T cells, which was then analyzed for CD4+ and CD8+. 
Both populations were gated on Va7.2+CD161+ and the proportion and number of MAIT cells 
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were calculated. All gating analyses were performed using FlowJo (Ashland, OR, USA). 
Circulating cell number was determined by multiplying the percentage of lymphocytes 
expressing the markers of interest with the hematology total lymphocyte count for each 
population.  
 
A. B.  C.  
D.  E.  F.  G.  
 
Figure 3. Gating strategy for MAIT cell and cytokine identification. A. Single cells. B. Side Scatter-
Forward Scatter plot used to select lymphocytes. C. CD3+ T cells D. CD3+ and CD8+ Cytotoxic T cells 
E. MAIT cells were identified as Vα7.2+CD161+ cells. F. TNF-α expression in MAIT cells. G. IFN-γ 
expression in MAIT cells. 
 
Statistical Analysis 
 Data collected was analyzed with Jamovi Statistics Version 0.9 (Jamovi Project 
Computer Software, 2018). The α level was set a priori for all statistical procedures at α = 0.05. 
Descriptive statistics were used to summarize subject characteristics and values were reported as 
mean ± SD. One-way ANOVAs were used to compare between group analyses for participant 
characteristics and physiological responses to the VO2peak test and exercise trial. One-sample t-
tests were used to analyze plasma volume shifts from baseline to immediately post-exercise and 
1-hour post-exercise in comparison to zero. 2x3 mixed model repeated measures ANOVAs were 
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used to compare hematological data at three separate time points: pre-exercise, immediately 
post-exercise, and one-hour after exercise between two separate groups: BrCa survivors and 
healthy age-matched controls. If the interactions were significant, simple effects were used to 
determine where the differences exist. The main effects of time and group were examined in the 
absence of an interaction. A Bonferroni post-hoc analysis was performed to determine specific 
























15 sedentary controls and 21 BrCa survivors completed the study. Physical characteristics 
for the 36 participants are presented in Table 2. The two groups were age-matched (P = 0.185). 
Although self-reported physical activity prior to participating in the study was different between 
groups (Figure 4), cardiorespiratory fitness, reported as relative VO2peak, was not different 
between groups (P = 0.865) (Table 3).  
 
 
Figure 4. Average levels of physical activity (PA) per week prior to study participation. 






HR, RPE, workload, and metabolic responses to VO2peak test and the 45-minute acute 
exercise trial are presented in Table 3. Relative VO2peak (P = 0.865), absolute VO2peak (P = 
0.651), and peak heart rate (P = 0.889) achieved were similar between groups. All exercise trials 
were completed at 60% of VO2peak wattage, with an average workload of 75.4 watts in controls 
and 70.4 watts in BrCa survivors. Additionally, exercise trial average HR (P = 0.524), percent of 
peak HR (P = 0.703), and RPE (P = 0.339) were all similar between groups. The exercise trial 
was reported as “very hard,” based on an average RPE of 18.3 (controls) and 16.9 (BrCa 
survivors). 
 
Table 2. Participant characteristics      
  
Controls 
(n=15)   
BrCa      
(n=21)   
P value 
Age (years) 52 ± 9  57 ± 9  0.185 
Height (cm) 161 ± 4.5  165.4 ± 6.7  0.036 
Total Body Mass (kg) 74.3 ± 14.6  74 ± 12.2  0.951 
Lean Mass (kg) 42.7 ± 7.4  37.4 ± 6.3  0.645 
Body Fat (%) 39.3 ± 4.6  40.4 ± 6.3  0.566 
Postmenopausal Participants (%) 53%  76%   
BrCa Stage (# of women)      
I   5   
II   8   
III   7   
Time Since Diagnosis (months)   11 ± 4.9   
Medical Treatment Before Study     
Surgery (%)   21 (100%)   
Radiation Therapy (%)   18 (86%)   
Chemotherapy   15 (71%)   
Endocrine Therapy   16 (76%)   
Current Endocrine Therapy Use   12 (57%)   
Time Since Primary Treatment End (months)     7 ± 4.1     
Abbreviations: BrCa, Breast Cancer Survivor.      
Reported as mean ± standard deviation.      
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Table 3. Physiological response to VO2peak test and the exercise trial consisting of 10 sets of 
cycling at 60% of peak wattage for 3 minutes followed by 1.5 minutes of passive recovery. 
  Controls (n=15)   BrCa (n=21)   P value 
Absolute VO2peak (L/min) 1.6 ± 0.4  1.6 ± 0.4  0.651 
Relative VO2peak (mL/kg/min) 21.5 ± 2.3  21.2 ± 5.6  0.865 
Peak Heart Rate (bpm) 159.2 ± 11.9  158.5 ± 16.9  0.889 
Peak RPE 18.3 ± 1.4  16.9 ± 1.9    0.011 
Peak Workload (watts) 125.8 ± 19.8  117.2 ± 26.3  0.274 
Trial Workload (watts) 75.4 ± 11.8  70.4 ± 15.8  0.283 
Average Exercise Trial HR (bpm) 142.9 ± 11.2  137.4 ± 31.6  0.524 
Average Exercise Trial % Peak HR 89.8 ± 4.1  90.6 ± 7.2  0.703 
Average Exercise Trial RPE 13.3 ± 1.4   12.6 ± 2.4   0.339 
Abbreviations: BrCa, Breast Cancer Survivor; VO2peak, peak oxygen uptake; HR, heart rate; RPE, Rate of Perceived Exertion. 
Reported as mean ± standard deviation.      
      
 
Changes in Leukocyte Counts 
 Cell counts for total leukocytes, lymphocytes, mixed cells, and neutrophils, as well as 
plasma volume shifts at each time point are presented in Table 4. Leukocyte counts were not 
available 1-hour post-exercise for 2 BrCa survivor participants and 1 control participant due to 
difficulties in cannulation. These missing samples accounted for a small percentage, and 
accepted statistical procedures allowed for appropriate analysis despite the missing data points. 
All leukocyte populations significantly increased from pre-exercise to immediately post-exercise 
(P < 0.001) and returned to baseline values 1-hour following the exercise bout (P < 0.001). 
Exercise and recovery patterns from leukocytes and leukocyte subsets were largely similar 
between controls and BrCa survivors, with the exception of lymphocyte counts that were 
significantly different between groups (P < 0.001). Main effects for time differences were 
analyzed for each group. At 0-hour, controls increased lymphocyte number by 35% (0.7 x 103 





From 0-hour to 1-hour following the exercise bout, controls decreased by 33.3% (-0.9 x 103, (P < 
0.001), and BrCa by 44.4% (-0.8 x 103, (P < 0.001). A significant group x time interaction was 
present for mixed cell counts (P = 0.048). Immediately post-exercise, controls increased by 50% 
(0.2 x 103, P < 0.001), and BrCa increased by 60% (0.3 x 103, P < 0.001). From 0-hour to 1-hour 
following the exercise bout, controls decreased by 16.7% (-0.1 x 103, P < 0.001), and BrCa by 
50% (-0.4 x 103, P < 0.001). Lymphocyte counts were statistically different between BrCa and 
controls (P < 0.001). 
 
Table 4. Complete blood cell counts and plasma volume shifts across time.      
    Base 0-hour 1-hour   G x T Group Time 
Leukocytes  
(x 103/µL) 
CON 5.8 ± 1.5 7.8 ± 2.4 6.2 ± 1.3  0.865 0.157 <0.001 
 BrCa 4.8 ± 1.7 6.9 ± 2.4 5.6 ± 2.0     
Lymphocytes  
(x 103/µL) 
CON 2.0 ± 0.6 2.7 ± 1.0 1.8 ± 0.5  0.842 <0.001 <0.001 
 BrCa 1.1 ± 0.4 1.8 ± 0.7 1.0 ± 0.3     
Mixed Cells  
(x 103/µL) 
CON 0.4 ± 0.2 0.6 ± 0.2 0.5 ± 0.2  0.048 0.233 <0.001 
 BrCa 0.5 ± 0.2 0.8 ± 0.7 0.4 ± 0.2     
Neutrophils  
(x 103/µL) 
CON 3.5 ± 1.1 4.5 ± 1.6 4.0 ± 1.0  0.358 0.759 <0.001 
 BrCa 3.1 ± 1.6 4.3 ± 2.0 4.2 ± 1.8     
Hemoglobin  
(g/dL) 
CON 12.5 ± 1.3 13.5 ± 1.5 12.3 ± 1.4  0.160 0.927 <0.001 
 BrCa 12.3 ± 1.1 13.4 ± 1.1 12.5 ± 0.9     
Hematocrit  
(%) 
CON 37.3 ± 2.8 41.0 ± 3.0 37.8 ± 2.7  0.547 0.587 <0.001 
 BrCa 36.9 ± 3.8 40.4 ± 2.9 37.7 ± 2.5     
PV Shift  
(%) 
CON - -12.0 ± 4.7 1.0 ± 4.5  - 0.599 <0.001 
 BrCa - -13.0 ± 6.2 -2.5 ± 7.0     
Abbreviations: BrCa, Breast Cancer Survivor; B, Baseline pre-exercise; 0h, immediately post-exercise; 1h, 1-hour 
post-exercise; PV, plasma volume. 
Reported as mean ± standard deviation.   




Plasma Volume Shifts 
Plasma volume shifts decreased by -12.0 ± 4.7 in controls and -13.0 ± 6.2 (both P <0.001, 
Table 4) in BrCa immediately following exercise before returning to baseline levels by 1-hour 
post-exercise. There were no differences between groups at 0-hour (P = 0.599) or 1-hour post-
exercise (P = 0.089).  
MAIT Cell Assays  
 MAIT cell function following the acute exercise bout was the primary outcome being 
investigated. A number of stimulation assays were conducted in effort to optimize the protocol. 
Young healthy females MAIT cells were used for the cellular assay protocol optimization due to 
convenience. During the initial stimulation, MAIT cells expressed 12.0% TNF-α and 16.9% 
IFN-γ. Given the low cytokine expression, an experiment comparing a 4-hour to an 8-hour 
stimulation incubation following the 12-hour rest period post-thaw with different doses of PMA 
was implemented. Dose response analysis using 2 ng/mL PMA, 10 ng/mL PMA, and 20 ng/mL 
PMA and 1 µg/mL ionomycin between the two stimulation-time conditions yielded similar 
results (4h: 9.57% TNF-α and 5.42% IFN-γ at 2 ng/mL PMA, and 11.59% TNF-α and 5.36% 
IFN-γ at 10 ng/mL PMA; 8h: 17.64% TNF-α and 4.86% IFN-γ at 2 ng/mL PMA, and 17.92% 
TNF-α and 6.06% IFN-γ at 10 ng/mL PMA. Non-cryopreserved cells were also stimulated for 4 
hours with dose response analysis to 2 ng/mL PMA, 10 ng/mL PMA, 50 ng/mL PMA, 100 
ng/mL PMA, and 1000 ng/mL PMA with 1 µg/mL ionomycin and 2 µL/mL of brefeldin A. 
MAIT cells expressed 19.12% TNF-α and 50.28% IFN-γ at 2 ng/mL PMA, 22.77% TNF-α and 
40.89% IFN-γ at 10 ng/mL PMA, 23.74% TNF-α and 31.31% IFN-γ at 50 ng/mL PMA, 18.73% 
TNF-α and 28.46% IFN-γ at 100 ng/mL PMA, and 0.10% TNF-α and 0% IFN-γ at 1000 ng/mL 
PMA (Figure 5). 
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Concurrent issues involving cell clumping following the thaws occurred, which lead to 
significant cell loss, so 10 µL deoxyribonuclease (DNAse) was added to the wash media used for 
the first centrifuge following thaw. Cells continued to clump, so a “rest-time following thaw” 
experiment that utilized DNAse in RPMI complete media for the initial wash and 
ethylenediaminetetraacetic acid (EDTA) in phosphate buffered saline (PBS) for the rest media 
was performed to prevent cell clumping. 1.25 µL DNAse/5 mL RPMI complete media was used 
to wash the cells immediately following the thaw. Cells were resuspended in 4 µL EDTA/1 mL 
PBS for rest times of 1, 2, 3, and 4-hours. Cells only demonstrated clumping during the 1-hour 
rest, so a 2-hour rest time was decided for future analyses with fresh new antibody.  
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Figure 5. TNF-α and IFN-γ cytokine expression in PMA Dose Experiment. A. TNF-α at 2ng PMA. B. TNF-α at 10 ng PMA. C. TNF-α 
at 50ng PMA. D. TNF-α at 100ng PMA. E. TNF-α at 1000ng PMA. F. IFN-γ at 2ng PMA. G. IFN-γ at 10 ng PMA. H. IFN-γ at 50ng 











This aim of this study was to examine immune response to an acute bout of moderate 
intensity intermittent aerobic exercise in a BrCa survivor population compared with healthy but 
sedentary age-matched controls. In support of our hypotheses, leukocyte counts significantly 
increased immediately following the exercise trial and returned to baseline 1-hour after exercise 
similarly in BrCa survivors and controls. Although MAIT cell stimulations were unsuccessful, 
progress was made towards optimizing protocol for future functional analyses. It is important to 
note that the control group was closely age matched, displayed nearly identical body composition 
and cardiorespiratory fitness profiles to the BrCa survivors, and the physical stress of the 
exercise trial, reported as trial workload, average HR, RPE, and percent of peak HR, was similar 
between groups. This is key as immune response tends to be directly proportional to exercise 
intensity (51, 54). However, because this acute exercise bout was intermittent, results may differ 
from responses to continuous exercise. Nonetheless, utilizing a standardized exercise intensity 
workload of 60% peak wattage for all participants allowed for valid interpretation of our study 
results. 
 The leukocyte response to acute exercise findings support outcomes in previous exercise 
immune-oncology studies. The BrCa survivors presented a significant increase in leukocyte and 
leukocyte subpopulation counts immediately following the acute bout of exercise, then decreased 
back towards baseline values during 1 hour of recovery. These cellular changes mirrored the 
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immune response patterns of the control group, but were overall consistently lower in 
comparison, particularly in lymphocytes. Immune cell count deficiencies are a hallmark 
characteristic in cancer patients post-treatment, so this suppressed immune response seen in the 
BrCa group may be due to the various cancer treatments they experienced prior to study 
participation (4, 19, 31, 59, 61, 71). The small number of studies that have examined immune 
response to acute exercise in cancer populations produced similar findings to this study. Shore 
and Shepard (63) and Ladha et al. (41) assessed changes in leukocyte counts in response to 30 
minutes of aerobic exercise in pediatric lymphoblastic leukemia patients. Shore and Shepard (63) 
participants exercised at VT whereas Ladha (41) participants exercised intermittently at 70-85% 
of VO2peak. Both studies reported significant leukocytosis immediately post-exercise and a return 
to baseline values during exercise recovery with cell counts lower in cancer patients but not 
significantly different than healthy matched controls. Additionally, Evans et al. (17) exhibited 
biphasic exercise and recovery patterns of leukocyte counts and plasma volume shifts, which 
were largely similar between BrCa survivors and a control group following 30 minutes of 
moderate intensity intermittent aerobic exercise on a cycle ergometer. It is worth noting that 
immediately post-exercise leukocyte counts were greater in the current study’s participants 
compared to Evans et al. (17) whom analyzed similar BrCa and healthy control populations. This 
was most likely due to our participants exercising at 60% of their VO2peak wattage whereas 
Evans’ participants exercised at 60% VO2peak. 60% peak wattage is roughly equivalent to 70% 
VO2peak, and thus this 10% increase in intensity may have provoked greater leukocytosis. BrCa 
participants were able to complete the acute exercise trial suggesting that this clinical population 
may be able to safely withstand high exercise intensities. In all, absolute counts and changes in 
counts following acute exercise from the current study were consistent with all of the above 
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considered studies, and in turn, are encouraging as they suggest this moderate-intensity and 
duration form of exercise is both tolerable and practical for recently treated BrCa survivors. 
 The purpose of this study did not involve direct exploration of potential physiological 
mediators for leukocyte response to the acute moderate-intensity intermittent aerobic exercise 
bout. However, it is suggested that leukocytosis during exercise is due to a synergistic effect of 
increases in circulating catecholamines that occurs with increased cardiac output and 
hemodynamics of shear mechanical forces that downregulate vascular endothelial-leukocyte 
adhesion (13, 64, 72). Although not measured in this study, similar protocols in BrCa (18) and 
prostate cancer survivors (30) have shown increases in catecholamines following acute exercise. 
The decrease in cell counts during recovery time may also be related to exercise-induced 
endocrine and immune system interactions. 
The MAIT cell stimulation assays in this project were mostly unsuccessful. Early 
protocol optimization assays produced limited findings, therefore stimulation assays to assess 
MAIT cell function were not conducted on the cryopreserved BrCa and healthy control 
participant cells from this study. The results of the trialed functional experiments yielded 
significant loss of cell numbers following thaws and low stimulation responses, that which did 
not correspond to previous findings in healthy young males (28). Exercise immunology literature 
postulates sex differences in immune function exist in response to aerobic exercise (24). The 
stimulation assay for this study was obtained from Hanson et al. (28), who successfully analyzed 
MAIT cell activation in response to acute aerobic exercise in healthy young males. The cells 
used during protocol optimization were those of healthy young females. It is possible that sex 
hormones interacted with aspects of the immune system, and lead to reduced immune function. 
Additionally, menstrual phase was not controlled for in the healthy young females during the 
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trial assays. Different phases of the menstrual cycle can illicit alterations in immune function 
(24). Both of these physiological variables may explain the perplexing results of the pilot 
experiments. 
Protocol optimization included PMA dose responses, rest and stimulation incubation 
times, and cell clumping experiments. Previous studies had successful stimulation of T cells and 
specifically MAIT cells using PMA and ionomycin (Table 1). A methodology optimization study 
stimulating T cells in rats reported that 25 ng/mL of PMA combined with 1 µg/mL of ionomycin 
incubated for 6 hours was the best TNF-α, IFN-γ, and IL-2 cytokine production method (1). 
Lancaster and colleagues (Lancaster et al. 2004) used 25 ng/mL of PMA with 1 µg/mL 
ionomycin in a 4-hour incubation to stimulate T lymphocytes to analyze IFN-γ cytokine response 
to exercise. Miyazaki et al. (Miyazaki et al. 2011) cultured MAIT cells from multiple sclerosis 
patients for 4 hours in 50 ng/mL PMA with 500 ng/mL ionomycin to examine intracellular 
cytokine expression, resulting in about 84% IFN-γ expression, and Hanson et al. (28) stimulated 
MAIT cells from healthy young males in response to acute submaximal aerobic exercise on a 
cycle ergometer for 4 hours in 2 ng/mL with 1 µg/mL ionomycin to produce about 70% TNF-α 
and 60% IFN-γ cytokine expression at baseline. The highest cytokine activation we 
accomplished in baseline blood samples from heathy young adults was 23.74% TNF-α at 50 
ng/mL PMA and 50.28% IFN-γ at 2 ng/mL PMA following a 4-hour stimulation. MAIT cell 
proportions tended to drop at higher doses of PMA stimulation. These higher doses of PMA may 
have been lethal to the cells causing cellular necrosis or alterations in receptor density. Doses of 
2 ng/mL and 10 ng/mL of PMA produced similar expression levels, and they did not lead to 
decreases in MAIT cell proportions. As such, these smaller doses yielded optimal stimulation 
results including MAIT cell proportions consistent with the literature. Although these are 
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preliminary findings, protocol optimization was moving in the right direction for future analyses 
in MAIT cell counts, frequencies, and function between BrCa survivors and healthy controls. 
 This study is one of few to describe immune response to acute exercise in a cancer 
population. As with any study, there are limitations to the present investigation. First, there was 
variation in BrCa stage, forms of cancer treatment, and study enrollment time since completion 
of treatment. All cancer participants had been diagnosed and treated for stage I to III non-
malignant BrCa, treated with chemotherapy, radiation, surgery, and/or endocrine therapy, and 
enrolled in this study within one year of completing treatment. However, physiological responses 
to exercise participation may differ for those with different cancer stages, forms of treatment, and 
longer recovery times since treatment therapies. Second, are the differences in physical activity 
between groups. A sedentary population was recruited as the control group because literature 
reports that cancer survivors tend to be less physically active than healthy persons. Contrarily, 
BrCa survivors in this study reported significantly higher physical activity habits prior to study 
participation than the age-matched controls, as illustrated in Figure 4. It is important to note that 
the IPAQ, a self-report physical activity questionnaire, was used to collect physical activity data, 
and self-report has its limitations as it is dependent on participant integrity. Although the IPAQ is 
a widely accepted and useful tool for measuring subjective physical activity, studies have shown 
that self-report questionnaires tend to report greater physical activity time than objective 
measured physical activity tools (16, 45, 68). A key strength was that the study sample was 
homogenous in nature with statistically significant similarities between groups in age, body 
composition, and fitness levels. In comparison to other exercise oncology studies, this study 
included a control group for data contrast, a moderate sample size (21 BrCa survivors and 15 
controls), and utilized a cycle ergometer for the exercise bout like other similar studies. An 
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additional limitation was the employment of a discontinuous exercise trial protocol, which may 
or may not have produced results consistent with that of a continuous protocol. Though, all 
participants were able to maintain 60% of their VO2peak wattage for the entirety of the exercise 
trial. Finally, all cellular assays were performed ex vivo. Although these assays have been 
successfully practiced in many studies, the methods used may not be able to mimic the in vivo 
biological environment. For cytokines detection in PBMC’s, the isolation and cell culture 
procedures may wash out important immune molecules, including cells themselves, and disrupt 
molecular interactions (1, 35). This is particularly important to consider in cancer patient 
samples as cellular processes may have been altered during cancer prognosis and treatment. 
It is well established that exercise has the ability to mobilize the immune system and 
activate cytotoxic immune cells that assist in immune regulation and pathogen defense in both 
healthy and oncology populations. The results of this study provide insightful information about 
cardiopulmonary and immune responses to exercise in individuals who have low 
cardiorespiratory fitness levels due to being sedentary and/or undergoing cancer treatment. As 
previously discussed, most major cancer treatments compromise the function of many 
physiological systems, including the immune system. Despite cancer treatment influences, BrCa 
survivors exercised at comparable intensities, that which produced immune responses similar to 
healthy matched controls. Immune response to acute exercise has not yet been systematically 
assessed in BrCa survivors. Therefore, there is a need for future studies to shed light on how 
various forms of acute exercise (varying in intensity, duration, interval vs continuous fashion, 
type, etc.) influence specific leukocyte response in cancer patients, including MAIT cells as they 
have yet to be successfully studied in females, older populations, or cancer populations. 
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In summary, 30 minutes of moderate-intensity intermittent aerobic exercise on a cycle 
ergometer elicited similar leukocyte responses in BrCa survivors to that of physically similar 
sedentary women without a history of cancer diagnosis. The present study was not able to assess 
MAIT cell function in BrCa survivors or the control group, though progress was made in 
optimizing the stimulation assay protocol for future analyses. Immunosuppression post-cancer 
treatment is a serious concern associated with secondary malignancies, increased illness 
susceptibility, and ultimately decreased quality of life. As exercise has been demonstrated as an 
effective form of alternative medicine capable of improving immune regulation, additional 
research investigating immune response to acute exercise is essential to better understand how 
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